Vor Biopharma (NASDAQ:VOR) Releases Quarterly Earnings Results, Misses Expectations By $0.64 EPS

Vor Biopharma (NASDAQ:VOR) released its earnings results on Friday. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.64), FiscalAI reports.

Vor Biopharma Trading Down 5.9%

Shares of NASDAQ VOR opened at $19.68 on Friday. The company has a 50-day moving average price of $20.75 and a 200-day moving average price of $17.33. Vor Biopharma has a 1 year low of $6.50 and a 1 year high of $26.76.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on VOR. Wedbush lifted their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. William Blair started coverage on shares of Vor Biopharma in a research report on Wednesday, October 21st. They set an “outperform” rating on the stock. Weiss Ratings upgraded Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 14th. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Citigroup raised Vor Biopharma to a “strong-buy” rating in a research report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Institutional Trading of Vor Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in Vor Biopharma during the 3rd quarter valued at $58,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Vor Biopharma by 25.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,795 shares of the company’s stock worth $198,000 after acquiring an additional 2,171 shares in the last quarter. Engineers Gate Manager LP raised its holdings in shares of Vor Biopharma by 37.5% in the second quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock valued at $680,000 after purchasing an additional 10,071 shares during the last quarter. Braidwell LP lifted its position in shares of Vor Biopharma by 22.8% during the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock valued at $10,551,000 after purchasing an additional 106,330 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in Vor Biopharma during the second quarter worth about $499,000. 97.29% of the stock is owned by institutional investors.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.